Dermatophagoides farinae
Identification
- Name
- Dermatophagoides farinae
- Accession Number
- DB10400
- Description
Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Allergenics
Allergen Extract - Synonyms
- American house dust mite
- American house dust mite extract
- House dust mite extract, dermatophagoides farinae
- Insects (whole body), mite dermatophagoides farinae
- Mite D.F.
- Mite D.F. (dermatophagoides farinae) standardized
Pharmacology
- Indication
Dermatophagoides farinae extract is an allergen extract indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to Dermatophagoidesfarinae house dust mites, or skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in adults 18 through 65 years of age
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
Treatment with ACTAIR has been shown to induce a systemic antibody response towards house dust mite allergens, with an increase in specific IgG4 antibodies in some patients. These immunoglobulins may compete with IgE for allergen binding, thereby decreasing allergen capture and presentation.
- Mechanism of action
The complete mechanisms of allergen immunotherapy are not clear and remain the subject of investigation. The allergic reaction is dependent on the presence of allergen-specific immunoglobulin E (IgE) antibodies that are bound to specific receptors on mast cells and basophils. The presence of IgE antibodies sensitizes these cells, and upon interaction with the appropriate allergens, histamine and other mediators are released which produce local or systemic responses in sensitive individuals, and characteristic symptoms of atopic diseases, such as allergic rhinitis and allergic asthma. Changes in serum antibody and T-lymphocyte responses resulting from immunotherapy have been demonstrated, and these changes often correlate closely with clinical (symptom) improvements. Specific mechanisms may vary depending on the nature of the allergic disease, the allergenic specificities of patients and populations, extract formulations, route of administration, dose and duration of treatment. Subcutaneous administration of allergenic extracts is known to elicit numerous immunological changes that are both time and dose-dependent. Many of these changes appear to be related to (or a precursor to) improvements in symptoms and other clinical parameters, as noted above. Specific changes found after immunotherapy with dust mite extracts include significant increases in mite-specific IgG4 antibodies, interleukin-10-positive T cells, and several T-cell receptors, and significant decreases in serum nitric oxide, eosinophil catonic protein, interleukin-4-positive T cells and IgE-mediated basophil histamine release.
- Absorption
Allergens in ACTAIR consist mainly of proteins and glycoproteins. There is no direct bioavailability of intact allergens in the blood. Therefore, no pharmacokinetic studies in animals or in humans have been carried out to investigate the pharmacokinetic profile and metabolism of ACTAIR.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Unlock Additional DataAllergenic Extract - Standardized Mite Dermatophagoides Farinae Liquid Intradermal; Subcutaneous Greer Laboratories Not applicable Not applicable Canada 
Allergenic Extract - Standardized Mite Dermatophagoides Farinae Liquid Intradermal; Subcutaneous Greer Laboratories 1999-03-15 Not applicable Canada Allergenic Extract Standardized Mite DF Liquid Subcutaneous Hollister Stier, Unit Pharm, Division Of Miles Canada Inc. 1992-12-31 1998-09-25 Canada Allergenic Extract Standardized Mite DF Liquid Subcutaneous Hollister Stier, Unit Pharm, Division Of Miles Canada Inc. 1992-12-31 1998-09-25 Canada Allergenic Extract Standardized Mite Df (10,000 Au/ml) Solution Percutaneous; Subcutaneous Jubilant Hollisterstier Llc 1998-01-16 Not applicable Canada Allergenic Extract Standardized Mite Df (30,000 Au/ml) Solution Percutaneous; Subcutaneous Jubilant Hollisterstier Llc 1997-01-03 Not applicable Canada Allergenic Extract, Standardardized Mite, D. Farinae Liquid Intradermal; Percutaneous; Subcutaneous Alk Abello, Inc. 1997-09-15 Not applicable Canada Allergenic Extracts - Standardized Mite Dermatophagoides Farinae Liquid Intradermal; Subcutaneous Greer Laboratories Not applicable Not applicable Canada House Dust Mite, Dermatophagoides farinae Injection 10000 [AU]/1mL Cutaneous; Intradermal; Subcutaneous Allermed Laboratories, Inc. 1986-12-24 Not applicable US 
Standardized Mite D Farinae Injection, solution 10000 [AU]/1mL Percutaneous; Subcutaneous Allergy Laboratories, Inc. 1989-01-25 Not applicable US Additional Data Available- Application NumberApplication NumberAvailable for Purchase
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct CodeAvailable for Purchase
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Acarizax Dermatophagoides farinae (6 unit) + Dermatophagoides pteronyssinus (6 unit) Tablet Sublingual Alk Abello A/S 2017-11-06 Not applicable Canada Allergen Pack Dermatophagoides Farinae Dermatophagoides farinae (15000 [AU]/1mL) + Sodium chloride (0.9 g/1mL) Kit Intradermal; Subcutaneous Alvix Laboratories 2015-07-21 2018-03-08 US Allergenic Extract - Standardized Mite Mix Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit) Liquid Intradermal; Subcutaneous Greer Laboratories 2002-08-20 Not applicable Canada Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml) Dermatophagoides farinae (15000 unit) + Dermatophagoides pteronyssinus (15000 unit) Solution Percutaneous; Subcutaneous Jubilant Hollisterstier Llc 1998-01-16 Not applicable Canada Allergenic Extract Mixture Of Standardized Mites (5,000 Au/ml) Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit) Solution Percutaneous; Subcutaneous Jubilant Hollisterstier Llc 1998-01-16 Not applicable Canada Allergenic Extract Standardized Mite Mix Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit) Liquid Subcutaneous Hollister Stier, Unit Pharm, Division Of Miles Canada Inc. 1992-12-31 1998-09-25 Canada Allergenic Extract Standardized Mite Mix Dermatophagoides farinae (15000 unit) + Dermatophagoides pteronyssinus (15000 unit) Liquid Subcutaneous Hollister Stier, Unit Pharm, Division Of Miles Canada Inc. 1992-12-31 1998-09-23 Canada Allergenic Extract, Standardized Mite Mixed Dermatophagoides farinae (5000 unit) + Dermatophagoides pteronyssinus (5000 unit) Liquid Intradermal; Percutaneous; Subcutaneous Alk Abello, Inc. 2006-02-28 Not applicable Canada Mixture of Standardized Mites Dermatophagoides farinae (5000 [AU]/1mL) + Dermatophagoides pteronyssinus (5000 [AU]/1mL) Injection, solution Intradermal; Subcutaneous Antigen Laboratories, Inc. 1991-10-22 Not applicable US Odactra Dermatophagoides farinae (6 [arb'U]/1) + Dermatophagoides pteronyssinus (6 [arb'U]/1) Tablet Sublingual ALK-Abello A S 2018-01-01 Not applicable US
Categories
- ATC Codes
- V01AA03 — House dust mites
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- PR9U2YPF3Q
- CAS number
- Not Available
References
- General References
- Liu L, Guo D, Liang Q, Ding S, Wu B, Zhang L, Li Q: The efficacy of sublingual immunotherapy with Dermatophagoides farinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy. 2015 Apr;45(4):815-22. doi: 10.1111/cea.12417. [PubMed:25258013]
- Eremina OIu, Stepanova GN: [The mechanism of action of permethrin on house dust mites]. Izv Akad Nauk Ser Biol. 1995 Jan-Feb;(1):72-9. [PubMed:7894317]
- Mauro M, Boni E, Makri E, Incorvaia C: Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. Expert Opin Drug Metab Toxicol. 2015;11(12):1937-43. doi: 10.1517/17425255.2015.1113255. Epub 2015 Nov 13. [PubMed:26565665]
- Drug information [Link]
- External Links
- PubChem Substance
- 347910575
- 1116977
- Wikipedia
- Dermatophagoides_farinae
- AHFS Codes
- 92:05.00* — Allergenic Extracts
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Recruiting Treatment Allergic Asthma Due to Dermatophagoides Pteronyssinus 1 3 Completed Treatment Respiratory Hypersensitivity 1 3 Completed Treatment Rhinoconjunctivitis 1 3 Recruiting Treatment Allergic Asthma Due to Dermatophagoides Farinae / Allergic Asthma Due to Dermatophagoides Pteronyssinus / Allergic Rhinitis Due to House Dust Mite 1 3 Recruiting Treatment Allergic Rhinitis (AR) / Rhinoconjunctivitis, Allergic 1 3 Recruiting Treatment Allergic Rhinitis Due to Dermatophagoides Farinae / Allergic Rhinitis Due to Dermatophagoides Pteronyssinus / Allergic Rhinitis Due to House Dust Mite 1 3 Recruiting Treatment Rhinoconjunctivitis, Allergic 1 Not Available Recruiting Not Available Allergic Asthma Due to Dermatophagoides Farinae / Allergic Asthma Due to Dermatophagoides Pteronyssinus / Allergic Rhinitis Due to House Dust Mite 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Oral 12 SQ-HDM Tablet, orally disintegrating Oral 6 SQ-HDM Injection, solution Subcutaneous 1000 TU/ml Tablet, orally disintegrating Oral 12 U Kit Intradermal; Subcutaneous Solution Percutaneous; Subcutaneous Liquid Subcutaneous Solution Percutaneous; Subcutaneous Liquid Subcutaneous Liquid Intradermal; Percutaneous; Subcutaneous Liquid Intradermal; Percutaneous; Subcutaneous Injection, suspension Subcutaneous 100 SQ-U/ml Injection, suspension Subcutaneous 2.5 ml Solution Sublingual 300 IR (U/Reactivity) Injection Cutaneous; Intradermal; Subcutaneous 10000 [AU]/1mL Tablet Sublingual Tablet Sublingual 50 SRU Injection, solution Percutaneous; Subcutaneous 10000 [AU]/1mL Injection, solution Subcutaneous 5000 [AU]/1mL Solution Percutaneous 10000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous 10000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous 30000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous 5000 [AU]/1mL Injection, solution Intradermal; Subcutaneous 10000 [AU]/1mL Concentrate Intradermal; Percutaneous; Subcutaneous Injection, solution Subcutaneous Liquid Intradermal; Subcutaneous Injection, solution Intradermal; Subcutaneous 3000 [AU]/1mL Injection, solution Intradermal; Subcutaneous 5000 [AU]/1mL Injection, solution Subcutaneous 10000 [AU]/1mL Injection, solution Intradermal 30 [AU]/1mL Injection, solution Intradermal 300 [AU]/1mL Injection, solution Percutaneous; Subcutaneous 30000 [AU]/1mL Liquid Intradermal; Subcutaneous Injection, solution Percutaneous Injection, solution Intradermal; Subcutaneous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 13:03 / Updated on January 25, 2021 22:38